In honor of Cancer Immunotherapy Month, the Foundation’s Chief Scientific Officer, Jessica Foley, PhD, talked with Jill O’Donnell-Tormey, PhD, CEO of the Cancer Research Institute (CRI) and Theresa LaVallee, PhD, VP of Translational Medicine and Regulatory Affairs at the Parker Institute for Cancer Immunotherapy (PICI) about the lifesaving potential of cancer immunotherapy and how CRI and PICI are working together and also with the Foundation to advance exciting new research and bring new treatments to patients.
The Cancer Research Institute and the Parker Institute for Cancer Immunotherapy are both leaders in the field of cancer immunotherapy and important partners to the Foundation. Dr. O’Donnell-Tormey and Dr. LaVallee are also members of the Foundation’s Cancer Immunotherapy Scientific Advisory Board.